Foley & Lardner LLP partner Louis Lehot shared insights on the factors fueling the biotech IPO rebound in the Mergermarket article, “Biotech IPO window widens as M&A fuels 2026 revival.”
Lehot noted that large pharmaceutical companies facing patent expirations are increasingly turning to acquisitions to replenish their pipelines.
“Once a drug demonstrates commercial potential, larger drugmakers can provide the sales and marketing infrastructure needed to scale the product and may ultimately acquire the developer, either before or after an IPO,” he said.
Related News
August 26, 2026
In the News
Gregory Husisian Addresses Refund Timelines, Litigation Trends, and Ongoing Tariff-Related Costs
Foley & Lardner LLP partner Gregory Husisian shared insights across the media on the recent surge in tariff refund litigation, ongoing uncertainty surrounding timelines, and how companies and consumers may be affected by tariff repayments.
August 24, 2026
In the News
James McKenna Garners Media Coverage Following CIO Appointment
Foley & Lardner LLP is pleased to share that James McKenna is featured across media following his appointment as the firm's Chief Information Officer (CIO).
August 21, 2026
In the News
Betsy Stone Discusses Federal EPR Challenges and Producer Implications
Foley & Lardner LLP senior counsel Betsy Stone shared insights in the Packaging Dive article, “California EPR lawsuit escalates as forthcoming Oregon ruling looms,” analyzing ongoing federal court challenges to extended producer responsibility (EPR) laws.